Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: J Hepatol. 2021 Feb 10;75(1):120–131. doi: 10.1016/j.jhep.2021.01.044

Fig. 3. Activation of Hippo by overexpression of LATS2 prevents loss of Tbx3 induced accelerated HCC growth in c-Met/β-Catenin HCC model.

Fig. 3.

(A) Study design. (B) Survival curves among c-Met/β-Catenin/pCMV, c-Met/β-Catenin/Cre/pT3, and c-Met/β-Catenin/Cre/Lats2 mice. (C) The liver weight and liver to body weight ratio among mouse cohorts. (D) Gross images, H&E staining, and immunohistochemical staining of Ki67 and SOX9 in mouse HCCs. (E) Western blot analysis of lysates from normal mouse livers (NL), mouse HCCs. GAPDH was used as a loading control. (F) Western blot analysis of nuclear lysates from mouse HCC tissues. β-Tubulin and Histone H3 were used as loading controls. (G) Relative mRNA levels of Lats2 and YAP/TAZ signaling targets (Ctgf, and Cyr61) in mouse HCCs. (H) Quantification of Ki67 positive cells in mouse HCCs. HTVi, hydrodynamic tail vein injection; Scale bar: 200 μm for 100x; 100 μm for 200x. n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (C, G) Mean ± SD; One-way ANOVA test. (H) Mean ± SD; Unpaired t-test.